CL2019000728A1 - Formas cristalinas. - Google Patents

Formas cristalinas.

Info

Publication number
CL2019000728A1
CL2019000728A1 CL2019000728A CL2019000728A CL2019000728A1 CL 2019000728 A1 CL2019000728 A1 CL 2019000728A1 CL 2019000728 A CL2019000728 A CL 2019000728A CL 2019000728 A CL2019000728 A CL 2019000728A CL 2019000728 A1 CL2019000728 A1 CL 2019000728A1
Authority
CL
Chile
Prior art keywords
crystalline forms
pharmaceutical compositions
forms
crystal
phosphonopropionil
Prior art date
Application number
CL2019000728A
Other languages
English (en)
Spanish (es)
Inventor
Raumer Markus Von
Daniel Leuenberger
Stefan Reber
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2019000728A1 publication Critical patent/CL2019000728A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2019000728A 2016-09-22 2019-03-21 Formas cristalinas. CL2019000728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22

Publications (1)

Publication Number Publication Date
CL2019000728A1 true CL2019000728A1 (es) 2019-07-05

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000728A CL2019000728A1 (es) 2016-09-22 2019-03-21 Formas cristalinas.

Country Status (27)

Country Link
US (4) US10730896B2 (cg-RX-API-DMAC7.html)
EP (2) EP3981774A1 (cg-RX-API-DMAC7.html)
JP (1) JP7097369B2 (cg-RX-API-DMAC7.html)
KR (1) KR102552795B1 (cg-RX-API-DMAC7.html)
CN (1) CN109715639B (cg-RX-API-DMAC7.html)
AU (1) AU2017331930B2 (cg-RX-API-DMAC7.html)
CA (1) CA3037794A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019000728A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125052T1 (cg-RX-API-DMAC7.html)
DK (1) DK3515924T3 (cg-RX-API-DMAC7.html)
EA (1) EA201990723A1 (cg-RX-API-DMAC7.html)
ES (1) ES2908572T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220234T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057772T2 (cg-RX-API-DMAC7.html)
IL (1) IL265445B2 (cg-RX-API-DMAC7.html)
LT (1) LT3515924T (cg-RX-API-DMAC7.html)
MA (1) MA46266B1 (cg-RX-API-DMAC7.html)
MX (1) MX381590B (cg-RX-API-DMAC7.html)
MY (1) MY193080A (cg-RX-API-DMAC7.html)
PH (1) PH12019500567B1 (cg-RX-API-DMAC7.html)
PL (1) PL3515924T3 (cg-RX-API-DMAC7.html)
PT (1) PT3515924T (cg-RX-API-DMAC7.html)
RS (1) RS62946B1 (cg-RX-API-DMAC7.html)
SI (1) SI3515924T1 (cg-RX-API-DMAC7.html)
TW (1) TWI752086B (cg-RX-API-DMAC7.html)
UA (1) UA124073C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018055016A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
US20240317784A1 (en) 2021-07-13 2024-09-26 Viatris Asia Pacific Pte. Ltd. Process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
OA12970A (en) 2002-12-11 2006-10-13 Schering Ag 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists.
PL1611144T3 (pl) 2003-04-09 2011-03-31 Wyeth Llc Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
BRPI0617636A2 (pt) 2005-10-21 2012-04-17 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
BRPI0810462A2 (pt) 2007-04-23 2014-10-14 Sanofi Aventis Derivados de quinolina-carboxamida como antagonistas de p2y12
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
CN102369197B (zh) 2009-04-08 2013-11-06 埃科特莱茵药品有限公司 作为adp受体拮抗剂的6-(3-氮杂-二环[3.1.0]己-3-基)-2-苯基-嘧啶
AU2010240527A1 (en) 2009-04-22 2011-12-01 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as P2Y12 receptor antagonists
AU2017331930B2 (en) 2016-09-22 2021-07-15 Viatris Asia Pacific Pte. Ltd. Crystalline forms
MX393334B (es) 2017-03-15 2025-03-24 Idorsia Pharmaceuticals Ltd Administración subcutánea de un antagonista del receptor p2y12.
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
TW201813965A (zh) 2018-04-16
WO2018055016A1 (en) 2018-03-29
MY193080A (en) 2022-09-26
HRP20220234T1 (hr) 2022-05-13
EP3515924B1 (en) 2021-12-15
IL265445B2 (en) 2024-05-01
US20200017534A1 (en) 2020-01-16
MX381590B (es) 2025-03-12
US20220275011A1 (en) 2022-09-01
CA3037794A1 (en) 2018-03-29
SI3515924T1 (sl) 2022-04-29
US20250163086A1 (en) 2025-05-22
PH12019500567B1 (en) 2024-01-31
HUE057772T2 (hu) 2022-06-28
IL265445A (en) 2019-05-30
PT3515924T (pt) 2022-03-11
JP2019529553A (ja) 2019-10-17
LT3515924T (lt) 2022-03-10
KR20190052704A (ko) 2019-05-16
MX2019003093A (es) 2019-07-18
AU2017331930B2 (en) 2021-07-15
PH12019500567A1 (en) 2019-11-18
RS62946B1 (sr) 2022-03-31
TWI752086B (zh) 2022-01-11
PL3515924T3 (pl) 2022-04-11
NZ750772A (en) 2023-10-27
US11365209B2 (en) 2022-06-21
US20210009614A1 (en) 2021-01-14
CY1125052T1 (el) 2024-02-16
EA201990723A1 (ru) 2019-10-31
US10730896B2 (en) 2020-08-04
ES2908572T3 (es) 2022-05-03
AU2017331930A1 (en) 2019-03-07
UA124073C2 (uk) 2021-07-14
KR102552795B1 (ko) 2023-07-06
EP3981774A1 (en) 2022-04-13
MA46266B1 (fr) 2022-02-28
BR112019004845A2 (pt) 2019-06-04
CN109715639A (zh) 2019-05-03
IL265445B1 (en) 2024-01-01
JP7097369B2 (ja) 2022-07-07
CN109715639B (zh) 2022-04-19
DK3515924T3 (da) 2022-03-21
MA46266A (fr) 2019-07-31
EP3515924A1 (en) 2019-07-31
US12227532B2 (en) 2025-02-18

Similar Documents

Publication Publication Date Title
SV2017005555A (es) Composiciones de acido obeticolico y metodos de uso
MX2019002049A (es) Compuestos de pirrolizina sustituidos y usos de los mismos.
CO2018004124A2 (es) Compuestos heterocíclicos
CL2017000786A1 (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
MX2020004024A (es) Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
MX2019015744A (es) Composiciones farmaceuticas.
CL2019000728A1 (es) Formas cristalinas.
MX379262B (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
SV2018005776A (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
MX367960B (es) Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificacion para su uso como principio activo farmaceutico.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MX2017002913A (es) Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dim etilbenzofuran-3-carboxamida.
CL2019002840A1 (es) Formas cristalinas de (s)-afoxolaner.
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
CO2018002364A2 (es) Una novedosa forma de isoxadifeno-etilo, un proceso para su preparación y uso de la misma